We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Dasatinib In Waldenström Macroglobulinemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04115059
Recruitment Status : Recruiting
First Posted : October 3, 2019
Last Update Posted : March 24, 2022
Bristol-Myers Squibb
Information provided by (Responsible Party):
Jorge J. Castillo, MD, Dana-Farber Cancer Institute

Brief Summary:
This is Phase I pilot, single center study designed to explore the safety of Dasatinib in symptomatic Waldenström Macroglobulinemia participants who are progressing on ibrutinib therapy with BTK Cys481 or PLCG2 mutations

Condition or disease Intervention/treatment Phase
Waldenstrom Macroglobulinemia DASATINIB Drug: Dasatinib Phase 1

Detailed Description:

This research study is a Pilot Study, which is the first time investigators are examining this drug in patients with Waldenström Macroglobulinemia who have progressed on ibrutinib.

Patients who fulfill eligibility criteria will be entered into the trial to receive Dasatinib

After the screening procedures confirm participation in the research study:

The participant will be given a study drug-dosing calendar for each treatment cycle. In this research study, the investigators are planning to give Dasatinib, which is a targeted therapy intended to treat cancer by binding to the target protein called BTK.

  • BTK is believed to be an important target for treatment of patients with specific gene mutations. Some patients who have disease progression after taking ibrutinib have these gene mutations.
  • Making treatment decisions based on genetic testing is investigational, and the FDA has not approved this genetic testing.

The U.S. Food and Drug Administration (FDA) has not approved Dasatinib for Waldenström Macroglobulinemia but it has been approved for other uses.

Dasatinib is produced by Bristol-Myers Squibb.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Dasatinib in Patients With Waldenström Macroglobulinemia (WM) Progressing on Ibrutinib
Actual Study Start Date : November 4, 2019
Actual Primary Completion Date : March 1, 2022
Estimated Study Completion Date : March 1, 2024

Arm Intervention/treatment
Experimental: Dasatinib

-- After the screening procedures confirm participation in the research study: The participant will be given a study drug-dosing calendar for each treatment cycle.

Dasatinib: Oral Study Drug(s):

  • Each study treatment cycle lasts 4 weeks during which time you will be taking the study drug one time per day.
  • This will continue for up to 24 cycles.
Drug: Dasatinib
Oral, daily, dosing per protocol, once a day for cycle
Other Name: Sprycel

Primary Outcome Measures :
  1. To evaluate the toxicity profile of dasatinib in WM patients who progressed on ibrutinib with BTK or PLCG2 mutations. [ Time Frame: 2 years ]
    Number and type of toxicities experienced by patients related to dasatinib.

Secondary Outcome Measures :
  1. Overall Response Rate [ Time Frame: 2 years ]
    Proportion of patients with MR, PR, VGPR, or CR to therapy.

  2. Complete Response Rate [ Time Frame: 2 years ]
    Proportion of patients with CR

  3. Very good partial response rate [ Time Frame: 2 years ]
    Proportion of patients with VGPR to therapy. (VGPR is >90% reduction in serum IgM from baseline)

  4. Partial Response Rate [ Time Frame: 2 years ]
    Proportion of patients with PR to therapy. (PR is 50-89% reduction in serum IgM from baseline)

  5. Minimal Response Rate [ Time Frame: 2 years ]
    Proportion of patients with Minor Responses to therapy. (MR is 25-49% reduction in serum IgM from baseline)

  6. Stable Disease Rate [ Time Frame: 2 years ]
    Proportion of patients with Stable disease to therapy. (SD is <25% reduction in serum IgM from baseline).

  7. Progressive Disease Rate [ Time Frame: 2 years ]
    Proportion of patients with a best response of PD to therapy. (PD is >25% increase in serum IgM from baseline).

  8. Progression Free Survival [ Time Frame: 2 years ]
    Kaplan Meier methodology

  9. Time to Next Therapy (TTNT) [ Time Frame: 2 years ]
    Kaplan Meier

  10. Overall Survival [ Time Frame: 2 years ]
    Kaplan Meier

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants must meet the following criteria on screening examination to be eligible to participate. Screening evaluations including consent, physical exam, and laboratory assessments will be done within 30 days prior to Cycle 1 Day 1. Bone marrow biopsy & aspirate, and CT C/A/P will be done within 90 days prior to Cycle 1 Day 1.
  • Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia
  • Known tumor expression of mutated MYD88 performed by a CLIA certified laboratory.
  • Participants must have a BTKCys481 and/or PLCγ2 mutation. Genomic alterations must be confirmed via sequencing performed at NeoGenomics Laboratories
  • At least one previous therapy, with ibrutinib as the most recent treatment. Participants may remain on ibrutinib therapy during screening. A 1 day washout before starting dasatinib is required.
  • Documented disease progression on last regimen (ibrutinib) per the Sixth International Workshop on WM. One or more of the following:
  • 25% increase in serum IgM level with at least 500 mg/dL absolute increase from nadir with re-confirmation
  • Progression of clinically significant disease related symptoms
  • Symptomatic disease meeting criteria for treatment using consensus panel criteria from the Second International Workshop on WM [26]. One or more of the following:

    • Constitutional symptoms
    • Progressive or symptomatic lymphadenopathy or splenomegaly
    • Hemoglobin <10 g/dL
    • Platelet count <100 k/uL
    • Symptomatic peripheral neuropathy
    • Systemic amyloidosis
    • Renal insufficiency
    • Symptomatic cryoglobulinemia
  • Age 18 years or older
  • Measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum serum IgM level of > 2 times the upper limit normal.
  • ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
  • Women of childbearing potential: Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or have or will have complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) while participating in the study; and 2) for at least 28 days after discontinuation from the study. FCBP must be referred to a qualified provider of contraceptive methods if needed.
  • Men must agree to use a latex condom during sexual contact with a female of childbearing potential (FCBP) even if they have had a successful vasectomy.
  • Participants must have normal organ and marrow function as defined below:

    • Absolute neutrophil count ≥500/ uL (Growth factor not permitted)
    • Platelets ≥50,000/ uL (Platelet transfusion not permitted)
    • Hemoglobin ≥ 7 g/dL (RBC transfusion permitted)
    • Total bilirubin ≤ 2 mg/dL
    • Potassium ≥ LLN
    • Magnesium ≥ LLN
    • AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal
    • Estimated GFR ≥ 30 ml/min
  • Able to swallow pills.
  • Able to adhere to the study visit schedule and other protocol requirements.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study:
  • Lactating or pregnant women.
  • Participants who are receiving any other investigational agents.
  • Prior therapy with BCR-ABL inhibitors.
  • Known CNS lymphoma.
  • Symptomatic hyperviscosity requiring urgent therapy.
  • Human Immunodeficiency Virus (HIV), active infection with Hepatitis B Virus (HBV), and/or Hepatitis C Virus (HCV).
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, pleural or pericardial effusion, unstable angina pectoris, cardiac arrhythmia, QT Prolongation, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Prolonged QTc interval on pre-entry electrocardiogram (> 450 msec)
  • History clinically significant ventricular arrhythmias such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes
  • Known history of alcohol or drug abuse
  • On any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin.
  • History of non-compliance to medical regimens.
  • Treatment with strong CYP3A4/5 inhibitors or inducers
  • Participants who are taking St. Johns Wort. Must discontinue at least 5 days before starting dasatinib.
  • Treatment with H2 Antagonists and proton pump inhibitors

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04115059

Layout table for location contacts
Contact: Jorge Castillo, MD (617) 632-4218 jorgej_castillo@dfci.harvard.edu

Layout table for location information
United States, Massachusetts
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Jorge J Castillo, MD    617-632-6045    Jorgej_castillo@dfci.harvard.edu   
Principal Investigator: Jorge J Castillo, MD         
Sponsors and Collaborators
Jorge J. Castillo, MD
Bristol-Myers Squibb
Layout table for investigator information
Principal Investigator: Jorge Castillo, MD Dana-Farber Cancer Institute
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jorge J. Castillo, MD, Sponsor Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT04115059    
Other Study ID Numbers: 19-305
First Posted: October 3, 2019    Key Record Dates
Last Update Posted: March 24, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: Data can be shared no earlier than 1 year following the date of publication
Access Criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jorge J. Castillo, MD, Dana-Farber Cancer Institute:
Waldenstrom Macroglobulinemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Waldenstrom Macroglobulinemia
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action